HK1202796A1 - Delivery system for specifically targeting cancer cells and method of use thereof - Google Patents

Delivery system for specifically targeting cancer cells and method of use thereof

Info

Publication number
HK1202796A1
HK1202796A1 HK15102888.4A HK15102888A HK1202796A1 HK 1202796 A1 HK1202796 A1 HK 1202796A1 HK 15102888 A HK15102888 A HK 15102888A HK 1202796 A1 HK1202796 A1 HK 1202796A1
Authority
HK
Hong Kong
Prior art keywords
delivery system
cancer cells
specifically targeting
targeting cancer
specifically
Prior art date
Application number
HK15102888.4A
Other languages
English (en)
Chinese (zh)
Inventor
．利拉德 詹姆斯．
Original Assignee
Jyant Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jyant Technologies Inc filed Critical Jyant Technologies Inc
Publication of HK1202796A1 publication Critical patent/HK1202796A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15102888.4A 2011-08-15 2015-03-21 Delivery system for specifically targeting cancer cells and method of use thereof HK1202796A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161523626P 2011-08-15 2011-08-15
PCT/US2012/049988 WO2013025418A1 (en) 2011-08-15 2012-08-08 Delivery system for specifically targeting cancer cells and method of use thereof

Publications (1)

Publication Number Publication Date
HK1202796A1 true HK1202796A1 (en) 2015-10-09

Family

ID=47712803

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102888.4A HK1202796A1 (en) 2011-08-15 2015-03-21 Delivery system for specifically targeting cancer cells and method of use thereof

Country Status (7)

Country Link
US (1) US20130045162A1 (xx)
EP (1) EP2744483B1 (xx)
JP (1) JP2014521743A (xx)
CN (2) CN104066425A (xx)
AU (1) AU2012295366B2 (xx)
HK (1) HK1202796A1 (xx)
WO (1) WO2013025418A1 (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012295366B2 (en) * 2011-08-15 2017-05-25 Jyant Technologies Delivery system for specifically targeting cancer cells and method of use thereof
FR3002451B1 (fr) * 2013-02-25 2015-06-26 Centre Nat Rech Scient Heterocycles phosphores analogues de sucres a activite antimetastatique
WO2017083659A1 (en) 2015-11-12 2017-05-18 New York University Biodegradable polymeric nanoparticle conjugates and use thereof
EP3426700B1 (en) * 2016-03-11 2021-12-15 The Regents of the University of California Engineered scaffolds for vascularized tissue repair
US10058093B2 (en) * 2016-03-29 2018-08-28 Jyant Technologies, Inc. Nanoformulations for plants
WO2019063705A1 (en) * 2017-09-27 2019-04-04 Targimmune Therapeutics Ag CANCER OF THE PROSTATE RESISTANT TO CASTRATION
EP3737415A4 (en) * 2018-01-12 2021-06-30 President and Fellows of Harvard College COMPOSITIONS AND PROCEDURES RELATED TO MACROPHAGE AND / OR MONOCYTE WITH ATTACHED PARTICLES
US10912843B2 (en) 2018-04-04 2021-02-09 National Cheng Kung University Endoplasmic reticulum-targeting nanovehicles and methods for use thereof
CN109350610B (zh) * 2018-12-12 2021-06-01 湖南湘源美东医药科技有限公司 一种姜黄素复合纳米颗粒及其制备方法
CN112237638B (zh) * 2020-10-28 2022-11-29 西安华牧生物科技有限责任公司 降低放射性核素肾浓聚的组合探针及其制备方法
WO2023172674A2 (en) * 2022-03-09 2023-09-14 The Regents Of The University Of California One-step supramolecular multifunctional coating on plant virus nanoparticles for bioimaging and therapeutic applications

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
EP1531159B1 (en) 2003-11-11 2005-10-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Peptide useful for diagnosis and therapy of tumors
WO2007109244A2 (en) * 2006-03-21 2007-09-27 Morehouse School Of Medicine Novel nanoparticles for delivery of active agents
US20080089941A1 (en) * 2006-06-01 2008-04-17 Mower Thomas E Fucoidan compositions and methods
CN101563105B (zh) * 2006-07-10 2013-01-23 拜奥根Idec马萨诸塞公司 用于抑制smad4-缺陷癌症的组合物和方法
US20100290982A1 (en) * 2007-04-13 2010-11-18 University Of North Texas Health Science Center At Fort Worth Solid in oil/water emulsion-diffusion-evaporation formulation for preparing curcumin-loaded plga nanoparticles
CN101917982B (zh) * 2007-11-12 2013-03-20 彼帕科学公司 使用4-碘-3-硝基苯甲酰胺与抗肿瘤剂组合治疗乳腺癌
US20090170195A1 (en) * 2007-12-28 2009-07-02 Kent State University Curcumin-hyaluronan compounds
US8685538B2 (en) * 2009-03-25 2014-04-01 Northeastern University Stable polyelectrolyte coated nanoparticles
AU2012295366B2 (en) * 2011-08-15 2017-05-25 Jyant Technologies Delivery system for specifically targeting cancer cells and method of use thereof
CN106580877A (zh) * 2016-08-31 2017-04-26 中国药科大学 一种水飞蓟宾纳米混悬剂及其制备方法

Also Published As

Publication number Publication date
CN110075316A (zh) 2019-08-02
US20130045162A1 (en) 2013-02-21
EP2744483A4 (en) 2015-06-24
AU2012295366B2 (en) 2017-05-25
EP2744483A1 (en) 2014-06-25
EP2744483B1 (en) 2020-04-29
WO2013025418A1 (en) 2013-02-21
AU2012295366A1 (en) 2014-03-27
JP2014521743A (ja) 2014-08-28
CN104066425A (zh) 2014-09-24

Similar Documents

Publication Publication Date Title
HRP20191463T8 (hr) Spojevi usmjereni na unos lijeka i poticanje sirna aktivnosti
IL262376A (en) Method and system for drug delivery
HK1249548A1 (zh) 用於無脈絡膜的基因療法的aav載體
HK1202796A1 (en) Delivery system for specifically targeting cancer cells and method of use thereof
EP2755720A4 (en) SYSTEMS AND METHODS FOR APNEA THERAPY
EP2844663A4 (en) Novel TETRAGALNAC-CONJUGATES AND METHOD OF RELEASING OLIGONUCLEOTIDES
EP2755614A4 (en) SYSTEMS AND METHOD FOR PROSTATE TREATMENT
EP2784953A4 (en) METHOD FOR THE HYBRID PROVISION OF MMT PAKCAGES AND CONTENTS AND METHOD FOR RECEIVING CONTENT
EP2569743A4 (en) SYSTEM AND METHOD FOR DIFFUSION OF ADVERTISEMENTS
EP2836501A4 (en) RNA APTAMERS FOR THERAPEUTIC AND DIAGNOSTIC ADMINISTRATION ON PANCREAS CRAB CELLS
HK1224147A1 (zh) 供給營養素的製劑和方法
IL233362A0 (en) Fluid administration system and its use
SG10201510009YA (en) Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer
ZA201203839B (en) Gas delivery system and gas delivery method
IL230998A0 (en) Drug release system and production methods
IL254182A0 (en) Drug release system and production methods
EP2661489A4 (en) METHOD FOR INCREASING THE DELIVERY OF GEN-TRANSDUCED CELLS
EP2692314A4 (en) STENT AND STONE FEEDING SYSTEM
HK1210307A1 (en) System and method for prescriber-centric targeting
HK1198470A1 (en) Drug delivery system and method of manufacturing thereof
GB201112636D0 (en) Delivery system and method
EP2709623A4 (en) MEDICINES AND METHODS FOR TREATING CANCER
EP2750691A4 (en) SRPX IN THE TREATMENT OF CANCER
WO2012138566A9 (en) Genetic determinants of prostate and breast cancer risk